Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta-analysis

被引:2
作者
Xiong, Ding [1 ,2 ]
Zhang, Kui [3 ]
Xu, Mingqing [1 ,2 ,4 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Hepatobiliary Surg, Chengdu 610064, Peoples R China
[2] Meishan Peoples Hosp, Meishan 620010, Peoples R China
[3] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Dept Forens Pathol, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Gen Surg, Chengdu, Peoples R China
关键词
Carcinoma; hepatocellular; Nivolumab; Meta-analysis; SORAFENIB;
D O I
10.23736/S0031-0808.21.04282-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
INTRODUCTION: Hepatocellular carcinoma (HCC) is the sixth most common cancer globally, and a major unresolved medical issue. According to the guideline recommendations of the European Association for the Study of the Liver in 2018 and the American Society for Clinical Oncology (ASCO) Guideline, nivolumab is a reasonable option for appropriate advanced stage HCC. EVIDENCE ACQUISITION: We searched the PubMed, Embase and CNKI (China National Knowledge Infrastructure) databases for all articles within a range of published years from 2010 to 2020 of nivolumab in advanced hepatocellular carcinoma and carried out this meta-analysis on all published studies to estimate prognostic factors of nivolumab in advanced hepatocellular carcinoma. EVIDENCE SYNTHESIS: Finally, 6 studies with 627 advanced hepatocellular carcinoma patients treated with nivolumab met the inclusion criteria for this study. Our results indicated that alpha-fetoprotein (AFP), eastern Cooperative Oncology Group (ECOG) performance status, Child-Pugh Class, portal vein invasion, protein induced by vitamin K absence-II (PIVKA-II), and albumin-bilirubin (ALBI) score were prognostic factor of nivolumab in advanced hepatocellular carcinoma; however, hepatitis C virus (HBV) infection, Barcelona Clinic Liver Cancer (BCLC) stage, and extrahepatic metastasis were not significant prognostic factors. CONCLUSIONS: Our meta-analysis indicated the potential prognostic factor of nivolumab in advanced hepatocellular carcinoma. However, ongoing clinical and translational research may provide us a better understanding of the prognostic factor and mechanisms. (Cite this article as: Xiong D, Zhang K, Xu M. Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta analysis. Panminerva Med 2023;65:506-10. DOI: 10.23736/S0031-0808.21.04282-8)
引用
收藏
页码:506 / 510
页数:5
相关论文
共 36 条
[1]   OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].
BEGG, CB ;
MAZUMDAR, M .
BIOMETRICS, 1994, 50 (04) :1088-1101
[2]   Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies [J].
Bruix, Jordi ;
Cheng, Ann-Lii ;
Meinhardt, Gerold ;
Nakajima, Keiko ;
De Sanctis, Yoriko ;
Llovet, Josep .
JOURNAL OF HEPATOLOGY, 2017, 67 (05) :999-1008
[3]   Non-invasive biomarkers for the detection of hepatocellular carcinoma [J].
Campion, Daniela ;
Tucci, Alessandra ;
Ponzo, Paola ;
Caviglia, Gian Paolo .
MINERVA BIOTECNOLOGICA, 2019, 31 (01) :11-22
[4]   Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis [J].
Caviglia, Gian Paolo ;
Ribaldone, Davide Giuseppe ;
Abate, Maria Lorena ;
Ciancio, Alessia ;
Pellicano, Rinaldo ;
Smedile, Antonina ;
Saracco, Giorgio Maria .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2018, 53 (06) :734-740
[5]   Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].
Chen, CJ ;
Yang, HI ;
Su, J ;
Jen, CL ;
You, SL ;
Lu, SN ;
Huang, GT ;
Iloeje, UH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73
[6]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[7]   Effectiveness and Safety of Nivolumab in Child-Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study [J].
Choi, Won-Mook ;
Lee, Danbi ;
Shim, Ju Hyun ;
Kim, Kang Mo ;
Lim, Young-Suk ;
Lee, Han Chu ;
Yoo, Changhoon ;
Park, Sook Ryun ;
Ryu, Min-Hee ;
Ryoo, Baek-Yeol ;
Choi, Jonggi .
CANCERS, 2020, 12 (07) :1-14
[8]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188
[9]   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502
[10]  
European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019